Oncology Landing 2015 Content

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

December 4th 2025

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Roman Fabbricatore

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

MRD May Predict Survival in Induction Chemotherapy AML Trials

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Russ Conroy

Efficacy Outcomes Remain Consistent Without Total Body Irradiation in B-ALL

Future work may expand analyses of measurable residual disease as a surrogate end point in AML to the use of modern, non-intensive treatment backbones.

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Ariana Pelosci

Catastrophic Income Loss Observed Among Families of Children with ALL

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Related Content

Alex Biese

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

December 4th 2025

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Roman Fabbricatore

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

MRD May Predict Survival in Induction Chemotherapy AML Trials

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Russ Conroy

Efficacy Outcomes Remain Consistent Without Total Body Irradiation in B-ALL

Future work may expand analyses of measurable residual disease as a surrogate end point in AML to the use of modern, non-intensive treatment backbones.

Ariana Pelosci